The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...

The company now expects vaccine sales to decline by low ... while sales of its shot for respiratory syncytial virus, Arexvy, plunged by 72% year over year. In a presentation, GSK attributed ...

TORONTO — Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults ...

GSK plc (LSE/NYSE: GSK), the global healthcare company, today announced preliminary data from ongoing clinical trials that suggest its respiratory syncytial virus (RSV) vaccine, Arexvy ...

GSK plc (LSE/NYSE: LON:GSK), the global healthcare company, today announced preliminary data from ongoing clinical trials that suggest its respiratory syncytial virus (RSV) vaccine, Arexvy ... Final ...

Fortunately, RSV vaccines are now approved for pregnant people ... Effectiveness: So far, real-world effectiveness data is ...

Arexvy performance was impacted by three factors ... so it's important Jemperli is now available to these patients. Zejula's growth continued in Q3 driven by U.S. pricing effects and high demand ...

Dont take the risk. Talk to your doctor or pharmacist about vaccination. AREXVY is now widely available at all major retail ...

On Thursday, GSK plc (NYSE:GSK) revealed new preliminary data for Arexvy (Respiratory Syncytial ... for RSV-LRTD until additional data became available. Price Action: GSK stock is down 0.53% ...

The flu shot and COVID-19 vaccine are available at participating pharmacies ... include additional vulnerable populations ...